CN103781482A - 用于调节细胞因子活性的方法 - Google Patents

用于调节细胞因子活性的方法 Download PDF

Info

Publication number
CN103781482A
CN103781482A CN201280030108.4A CN201280030108A CN103781482A CN 103781482 A CN103781482 A CN 103781482A CN 201280030108 A CN201280030108 A CN 201280030108A CN 103781482 A CN103781482 A CN 103781482A
Authority
CN
China
Prior art keywords
hydroxyl
hydrogen
oxo
halogen
coverlet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280030108.4A
Other languages
English (en)
Chinese (zh)
Inventor
上野隆司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Priority to CN201710153095.4A priority Critical patent/CN107028952A/zh
Publication of CN103781482A publication Critical patent/CN103781482A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280030108.4A 2011-04-19 2012-04-18 用于调节细胞因子活性的方法 Pending CN103781482A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710153095.4A CN107028952A (zh) 2011-04-19 2012-04-18 用于调节细胞因子活性的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161476992P 2011-04-19 2011-04-19
US61/476,992 2011-04-19
US201161489516P 2011-05-24 2011-05-24
US61/489,516 2011-05-24
US201161537305P 2011-09-21 2011-09-21
US61/537,305 2011-09-21
US201161548458P 2011-10-18 2011-10-18
US61/548,458 2011-10-18
PCT/JP2012/061004 WO2012144649A1 (en) 2011-04-19 2012-04-18 Method for modulating cytokine activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710153095.4A Division CN107028952A (zh) 2011-04-19 2012-04-18 用于调节细胞因子活性的方法

Publications (1)

Publication Number Publication Date
CN103781482A true CN103781482A (zh) 2014-05-07

Family

ID=47021806

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280030108.4A Pending CN103781482A (zh) 2011-04-19 2012-04-18 用于调节细胞因子活性的方法
CN201710153095.4A Pending CN107028952A (zh) 2011-04-19 2012-04-18 用于调节细胞因子活性的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710153095.4A Pending CN107028952A (zh) 2011-04-19 2012-04-18 用于调节细胞因子活性的方法

Country Status (13)

Country Link
US (1) US20120270945A1 (enExample)
EP (1) EP2699244A4 (enExample)
JP (1) JP2014511825A (enExample)
KR (1) KR20140043075A (enExample)
CN (2) CN103781482A (enExample)
AU (2) AU2012246999A1 (enExample)
BR (1) BR112013026644A2 (enExample)
CA (1) CA2831869A1 (enExample)
IL (1) IL228700A0 (enExample)
MX (1) MX2013012251A (enExample)
RU (1) RU2013151166A (enExample)
TW (1) TW201247615A (enExample)
WO (1) WO2012144649A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
JP6090723B2 (ja) * 2013-10-04 2017-03-08 国立大学法人東北大学 腎機能障害の予防又は改善剤
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454429A2 (en) * 1990-04-27 1991-10-30 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
JPH1029942A (ja) * 1996-04-02 1998-02-03 Yoichi Ichikawa 慢性関節リウマチ治療剤
CN101180096A (zh) * 2005-03-21 2008-05-14 苏坎波公司 用于治疗粘膜疾病的方法和组合物
CN101686985A (zh) * 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
EP2305304A1 (en) * 2008-04-28 2011-04-06 National University Corporation Hamamatsu University School of Medicine Immunopotentiating agent comprising ep1 agonist

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
NZ556710A (en) * 2005-01-27 2010-08-27 Sucampo Ag Method and composition for treating central nervous system disorders
NZ561414A (en) * 2005-03-04 2010-10-29 Sucampo Ag Method and composition for treating peripheral vascular diseases
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物
NZ608823A (en) * 2010-10-15 2014-11-28 Scinopharm Kunshan Biochemical Technology Co Ltd Processes for preparation of lubiprostone

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454429A2 (en) * 1990-04-27 1991-10-30 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
JPH1029942A (ja) * 1996-04-02 1998-02-03 Yoichi Ichikawa 慢性関節リウマチ治療剤
CN101180096A (zh) * 2005-03-21 2008-05-14 苏坎波公司 用于治疗粘膜疾病的方法和组合物
CN101686985A (zh) * 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
EP2305304A1 (en) * 2008-04-28 2011-04-06 National University Corporation Hamamatsu University School of Medicine Immunopotentiating agent comprising ep1 agonist

Also Published As

Publication number Publication date
EP2699244A1 (en) 2014-02-26
AU2017203276A1 (en) 2017-06-08
CN107028952A (zh) 2017-08-11
IL228700A0 (en) 2013-12-31
JP2014511825A (ja) 2014-05-19
MX2013012251A (es) 2014-01-20
BR112013026644A2 (pt) 2016-12-27
KR20140043075A (ko) 2014-04-08
EP2699244A4 (en) 2014-10-22
WO2012144649A1 (en) 2012-10-26
US20120270945A1 (en) 2012-10-25
RU2013151166A (ru) 2015-05-27
NZ616027A (en) 2015-09-25
AU2012246999A1 (en) 2013-10-17
TW201247615A (en) 2012-12-01
CA2831869A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
KR100260573B1 (ko) 간담즙성 질병 치료제
AU2017203276A1 (en) Method for modulating cytokine activity
US5252605A (en) Promotion of wound-healing with 15-keto-prostaglandin compounds
NZ501834A (en) Prostaglandin derivatives 13,14-dihydro-17-(3-fluorophenyl)-18,19,20-trinor-PGF2 for the treatment of glaucoma without increased melanin concentration in the eyes (iris)
US5164415A (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
CN101686984A (zh) Nsaid与前列腺素化合物的药物组合
US5346921A (en) Treatment of inflammation with 15-keto-prostaglandin compounds
JP2004504350A (ja) 高眼圧症および緑内障処置用組成物
AU2006209072B2 (en) Method and composition for treating central nervous system disorders
CN1867310B (zh) 促进毛发生长的组合物及其用途
AU2017203092B2 (en) Method for treating schizophrenia
JPH0848665A (ja) 肝・胆道系疾患処置剤
RU2577700C2 (ru) Фармацевтическая комбинация для лечения опухоли
NZ616027B2 (en) Method for modulating cytokine activity
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease
TW201347757A (zh) 治療帶有腹瀉之腸躁症之方法
WO2012148002A1 (en) Method for modulating ion transporter
TW201705952A (zh) 包含脂肪酸衍生物的醫藥組成物
HK1196278A (en) Method for treating schizophrenia
CN103974705A (zh) 用于炎症性疾病、过敏性疾病和自身免疫性疾病的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140507

RJ01 Rejection of invention patent application after publication